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Background and Objectives. This multinational retrospective
study compares the outcomes of patients with primary medi-
astinal large B-cell lymphoma (PMLBCL) with sclerosis after
first-generation (dose-intensive regimens), third-generation
(alternating regimens) and high-dose chemotherapy strate-
gies, frequently with adjuvant radiation therapy.
Design and Methods. Between August 1981 and December
1999, a total of 426 previously untreated patients with con-
firmed diagnosis were enrolled in 20 institutions to receive
combination chemotherapy with either first generation
(CHOP or CHOP-like) regimens, third generation (MACOP-
B, VACOP-B, ProMACE CytaBOM) regimens or high-dose
chemotherapy (HDS/ABMT).
Results. With chemotherapy, complete response (CR) rates
were 49% (50/105), 51% (142/277) and 53% (23/44)
with first generation, third generation and high-dose
chemotherapy strategies, respectively; partial response (PR)
rates were 32%, 36% and 35%, respectively. All patients
who achieved CR and 124/142 (84%) with PR had radia-
tion therapy on the mediastinum. The final CR rates became
61% for CHOP/CHOP-like regimens, 79% for MACOP-B and
other regimens, and 75% for HDS/ABMT. After median fol-
low-ups from attaining CR of 48.5 months for CHOP/CHOP-
like regimens, 51.7 months for MACOP-B type regimens and
32.4 months for HDS/ABMT, relapses occurred in 15/64
(23%), 27/218 (12%) and 0/33 (0%) patients, respec-
tively. Projected 10-year progression-free survival rates were
35%, 67% and 78%, respectively (p=0.0000). Projected
10-year overall survival rates were 44%, 71% and 77%,
respectively (p=0.0000), after median follow-ups from diag-
nosis of 52.3 months, 54.9 months and 35.8 months,
respectively.
Interpretation and Conclusions. In patients with PMLBCL
with sclerosis, MACOP-B plus radiation therapy may be a
better strategy than other treatments; these retrospective
data need to be confirmed by prospective studies. The
In the new Revised European American Lym-phoma (R.E.A.L.) classification,1 primary medi-astinal large B-cell lymphoma (PMLBCL) with
sclerosis is listed as a specific clinical and patho-
logic entity. Histologically, this lymphoma is char-
acterized by a diffuse proliferation of large B-cells
with clear cytoplasm and by the presence of a vari-
able degree of sclerosis, which causes the typical
compartmentalization pattern.2,3,4 Clinically, there
is a predominant female to male ratio, and patients
are commonly in the 25- to 40-year age group.
PMLBCL with sclerosis presents as a rapidly grow-
ing invasive tumor with contiguous spread within
mediastinal masses. Chest pain, cough, and dyspnea
are common. B symptoms are frequently present,
and 30% to 40% of patients have superior vena
cava obstruction. Pleural and pericardial invasion
with effusion are common. The lesion is frequently
bulky and often involves the thymus. Although
PMLBCL with sclerosis was originally believed to
have a particularly adverse prognosis, the outcome
of patients who receive chemotherapy or combined
modality treatment is now considered equivalent
to that of patients with other large cell lymphomas
of equivalent stage. Treatment with first-generation
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encouraging survival results after high dose chemotherapy
require confirmation in selected high-risk patients.
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chemotherapy regimens such as CHOP or CHOP-like
protocols5-11 and, more recently, third-generation
regimens (alternating regimens) such as the
MACOP-B protocol (dose-intensive regimens) has
been reported.12-20 The role of high-dose chemo-
therapy with rescue of peripheral blood stem cells
or autologous bone marrow is uncertain.21-23 Fisher
et al.24 have reported that CHOP and intensive third-
generation regimens produce equivalent results. This
observation may limit discussion about the use of
more aggressive protocols for PMLBCL with sclero-
sis. However, the debate is still open, because it is
difficult to compare the advantages of the different
types of protocols and it is also difficult to explain
the rather different complete response and survival
rates reported by different institutions using simi-
lar regimens. Although the value of adjuvant radia-
tion therapy after chemotherapy requires confirma-
tion, it could play an important role in the achieve-
ment of long-term progression-free survival (PFS),
especially in patients with bulky disease at presen-
tation.25-27 In this retrospective multinational study,
we report on 426 patients with a confirmed diag-
nosis of PMLBCL with sclerosis and their relative
responses to three different induction strategies:
first-generation, third-generation and high-dose
chemotherapy.
Design and Methods
Patients
Between August 1981 and December 1999, a total
of 426 patients with previously untreated PMLBCL
with sclerosis were admitted to 20 institutions (17
in Italy, 2 in England, 2 in Switzerland and 1 in
Greece) to receive combination chemotherapy with
either first-generation (105 patients), third-genera-
tion (277 patients) or high-dose (44 patients) pro-
tocols. All the centers kept treating patients accord-
ing to the chemotherapy regimen locally adopted at
that time. As a consequence, all the 426 patients
reported here were eligible for this retrospective
analysis. Histologic preparations of more than 300
cases were preserved in the archives of the institu-
tions involved. They were reviewed by local expert
pathologists according to the criteria of the R.E.A.L.
classification,1 and were all found to fulfill the stan-
dards for the diagnosis of PMLBCL with sclerosis. On
the basis of this confirmatory analysis, the cases
without recorded pathologic material were also
regarded as bona fide examples of the tumor. More
than 280 cases were involved in a pathologic study
with central review. In all cases, staging evaluation
included initial hematologic and chemical survey, in
addition to chest X-rays, computerized tomography
(CT) of the chest and abdomen, and bone marrow
biopsy. Bulky disease was defined as a tumor mass
≥6 cm. Staging and definition of extranodal sites
were based on the Ann Arbor classification.28 The
overall characteristics of the 426 patients with
respect to the three treatment subsets are shown in
Table 1, while Table 2 summarizes the patients’ dis-
tribution with respect to the International Prognos-
tic Index (IPI) score.29
Treatment subsets
In the first-generation subgroup (105 cases), 90
were treated with CHOP (cyclophosphamide, dox-
orubicin, vincristine and prednisolone)30 and 15 with
CHOP-B (cyclophosphamide, doxorubicin, vin-
cristine, prednisolone, and bleomycin).31 In the third-
generation subgroup (277 cases), 204 patients were
treated with MACOP-B (methotrexate, adriamycin,
cyclophosphamide, vincristine, prednisone, and
bleomycin),32 34 with VACOP-B (a MACOP-B-like
regimen with etoposide instead of methotrexate),33
and 39 with ProMACE CytaBOM (cyclophosphamide,
doxorubicin, etoposide, prednisone, cytarabine,
bleomycin, vincristine, and methotrexate).34 In the
high-dose treatment subgroup (44 cases), 27
patients received the high-dose sequential (HDS)
regimen as reported by Gianni et al.35 and 17 were
submitted to autologous bone marrow transplanta-
tion (ABMT) (as front-line treatment). Radiation
therapy was given to 339 (80%) patients including
all those who achieved CR; it was always started
four to six weeks after the last cycle of induction
chemotherapy, and was limited to the original sites
of involvement with a dose of radiation ranging
from 30 to 40 Gy over four to five weeks.
Assessment of response
All patients were restaged with chest and
abdomen CT two to four weeks after completion of
chemotherapy. Thereafter, all patients submitted to
radiation therapy were restaged with chest CT about
one month after the completion of treatment. Com-
plete response (CR) was defined as the complete
disappearance of signs and symptoms due to dis-
ease, as well as the normalization of all previous
abnormal investigations. Partial response (PR) was
defined as at least 50% reduction of known disease
with disappearance of the systemic manifestations.
No response was defined as anything less than PR.
Statistical analysis
All survival data were censored at the closing date
or the date of last contact when this preceded the
closing date. Overall survival (OS) was calculated by
the Kaplan-Meier method36 from the date of diag-
nosis (starting time) until last contact or death from
1259
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any cause (event). PFS was calculated for patients
who achieved a response after the first-line thera-
py from the date of first response to the date of last
contact, if alive and non-progressed, or to relapse or
death (events), whichever came first. Univariate
analysis was performed by the log-rank test37 or
Cox’s proportional hazard regression model,38 as
appropriate. Multivariate analysis was performed by
a Cox model using a stepwise selection method. The
χ2 test was used whenever appropriate for compar-
ison of subgroups. Two-sided p values were used
throughout.
Results
The treatment outcome according to the different
therapeutic approaches is summarized in Table 3.
After induction chemotherapy, the CR rate was 49%
(50/105) for first-generation chemotherapy
(CHOP/CHOP-like), 51% (142/277) for third-gener-
ation chemotherapy (MACOP-B etc) and 53%
(23/44) for high-dose chemotherapy (HDS/ABMT);
the overall CR rate was 51% (215/426). The PR rates
were 32%, 36% and 35%, respectively (35%;
148/426 globally). The overall response rates were
81% (83/105), 87% (242/277) and 88% (38/44),
respectively (85%; 363/426 globally). The remaining
63 (15%) patients showed progression of disease
during treatment. All the 215 patients who achieved
CR received radiation therapy to the mediastinum,
as did 124/148 (84%) patients who had a PR. After
the radiation therapy, 100/124 (81%) patients who
had already achieved a PR obtained CR status; thus,
the CR rates for the first-generation, third-genera-
tion and high-dose chemotherapy subgroups were
67% (14/21), 84% (76/90) and 77% (10/13), respec-
tively. Table 4 summarizes the outcome after radio-
therapy. Concerning the role of the combination of
anthracyclines plus radiation therapy in inducing
cardiac sequelae, it was impossible to have specific
data because of the retrospective nature of this
study. Relapses occurred in 15/64 (23%) patients
treated with first-generation chemotherapy, 27/218
(12%) in the third-generation subgroups and 0/33
(0%) in the high-dose subgroup (p=0.004 among
the three subgroups; p=0.02, first- vs. third-gener-
ation protocols). Globally, projected 10-year overall
survival (OS) was 65% (Figure 1) and 10-year PFS
was 62% (Figure 2). Projected 10-year OS of the
first-generation, third-generation and high-dose
chemotherapy subgroups was 44%, 71% and 77%,
respectively (Figure 3) (p=0.0000 among the three
subgroups; p=0.0001, first- vs. third-generation);
projected 10-year PFS was 35%, 67% and 78%,
respectively (Figure 4) (p=0.0000 among the three
1260
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Table 1. Characteristics of the 426 patients according to the
three main induction chemotherapy strategies.
First Third High-dose Total
generation generation HDS/ABMT
CHOP/ MACOP-B/VACOP-B/
CHOP-B ProMACE 
CytaBOM
N. patients 105 277 44 426
Sex M/F 37/68 113/164 15/29 165/261
Age median 35 35 30 32
range 19-87 13-82 15-72 13-87
Patients over 60 years (%) 9 5 9 5
B Symptoms 40 120 22 182
LDH abnormal 70 178 32 280
Performance status (%) ≤ 2 82 86 82 85
>  2 18 14 18 15
Mediastinal involvement 105 277 44 426 
(100%) (100%) (100%) (100%)
Abdominal involvement 9 (9%) 38 (14%) 3 (7%) 50 (12%)
Bulky mass 86 (82%) 225 (81%) 40 (91%) 351 (83%)
Site: mediastinal 84 213 38 339
nodal 1 4 2 1
abdominal 1 6 − 1
other − 2 − 2
Extranodal localization 38 (36%) 83 (30%) 15 (34%) 136 (32%)
Site: lung 16 37 9 58
kidney 3 6 2 11
other 19 40 4 63
Pleural effusion 31 (30%) 70 (25%) 16 (36%) 117 (27%)
Pericardial effusion 14 (13%) 37 (13%) 12 (27%) 63 (15%)
Superior vena cava syndr. 22 (21%) 68 (25%) 17 (39%) 107 (25%)
Stage I 25 (24%) 36 (13%) 2 (5%) 63 (15%)
II 49 (47%) 169 (61%) 33 (75%) 251 (59%)
III 6 (6%) 24 (9%) 3 (7%) 33 (8%)
IV 25 (24%) 48 (17%) 6 (14%) 79 (18%)
Bone marrow involvement 4 (4%) 14 (5%) 2 (5%) 20 (5%)
Table 2. Patients’ distribution with respect to the IPI score
in the three main chemotherapy subgroups.
IPI
Chemotherapy No. of 0 1 2 3 4 5
subgroup patients (%) (%) (%) (%) (%) (%)
First-generation 105 17 (16) 43 (41) 16 (15) 21 (20) 8 (8) −
Third-generation 277 57 (21) 113 (41) 56 (20) 37 (13) 11 (4) 3 (1)
High-dose 44 6 (14) 18 (41) 13 (30) 6 (14) 1 (2) −
Overall 426 80 (19) 174 (40) 85 (20) 64 (15) 20 (5) 3 (1)
Table 3. The treatment outcome after induction chemother-
apy according to the three main subgroups.
Chemotherapy
subgroups No. of pts. CR PR ORR
First generation 105 50 (49%) 33 (32%) 83 (81%)
Third generation 277 142 (51%) 100 (36%) 242 (87%)
High-dose 44 23 (53%) 15 (35%) 38 (88%)
Overall 426 215 (51%) 148 (35%) 363 (85%)
ORR: overall response rate.
subgroups; p=0.0003, first- vs. third-generation). As
regards OS, the median follow-up from diagnosis
for the first-generation, third-generation and high-
dose chemotherapy subgroups was 52.3 (range, 1-
202), 54.9 (range, 1-184) and 35.8 (range, 3-143)
months, respectively; as regards PFS, the median
follow-up after achievement of initial CR was 48.5
(range, 3-198), 51.7 (range, 6-180) and 32.4 (range,
18-136) months, respectively.
Univariate analysis was performed to identify poor
prognostic factors for OS and PFS. Male sex
(p=0.0032), poor performance status (p<0.00001),
increasing age (p=0.00001), stage III-IV disease
(p=0.00001), and the different chemotherapy induc-
tion (p=0.0001 among the three chemotherapy sub-
groups; p=0.00001 first- vs. third-generation pro-
tocols) were statistically significant poor prognos-
tic factors for OS. Increasing age (p=0.0036), poor
performance status (p=0.0334), and the induction
chemotherapy strategy (p=0.0621 among the three
subgroups) were found to adversely influence PFS.
Lactate dehydrogenase level was not significant for
the outcome. At multivariate analysis, all factors
remained significant for poor OS (Table 5), whereas
the only factor that remained significant for poor
PFS was increasing age (p=0.0106).
The fit of the IPI model to our set of patients was
good. Figure 5 shows the impact of IPI risk factors
(0-1 vs ≥2) on OS (p=0.0000).
Discussion
PMLBCL with sclerosis was first described as a dis-
tinct clinical-pathologic entity in the 1980s. It is
recognized in both the R.E.A.L1 and WHO39 classifi-
cations. The disease originates in the thymus, and
produces a large anterior mediastinal mass that can
lead to airway compromise and superior vena cava
syndrome. Although it resembles nodal large-cell
lymphomas, PMLBCL with sclerosis has discrete
morphologic, phenotypic and genetic features. It is
derived from thymic B-cells and is considered a
peripheral B-cell neoplasm. There have been no ran-
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Table 4. The therapeutic outcome with the inclusion of radi-
ation therapy.
Chemotherapy Patients who Conversions to CR Global CR after
subgroup achieved CR among patients chemotherapy
after CHT who received RT and RT
while in PR 
First-generation 50/105 (49%) 14/21 (67%) 64/105 (61%)
Third-generation 142/277 (51%) 76/90 (84%) 218/277 (79%)
High-dose 23/44 (53%) 10/13 (77%) 33/44 (75%)
Overall 215/426 (51%) 100/124 (81%) 315/426 (74%)
RT = radiation therapy; CHT = chemotherapy.
Figure 1. OS curve of all 426 patients with PMLBCL with
sclerosis.
Figure 2. PFS curve of all patients who obtained a CR after
combined modality therapy (induction chemotherapy plus
radiation therapy).
Figure 3. OS curves of the three main chemotherapy sub-
groups.
Figure 4. PFS curves of the three main chemotherapy sub-
groups.
years
years
years
years
domized treatment trials focusing on patients with
PMLBCL with sclerosis. However, the reports that do
exist40 permit some tentative conclusions to be
drawn. Use of first-generation chemotherapy (CHOP
or CHOP-like regimens) led to the early impression
that the prognosis of patients with PMLBCL with
sclerosis was worse than that of patients with the
more common diffuse large-cell lymphoma.5,11
However, with the application of more aggressive
combination chemotherapy programs (third-gener-
ation regimens), it appears that the CR, relapse-free
survival (RFS) and OS rates of patients with PMLB-
CL with sclerosis are at least as good and probably
better than those for diffuse large cell lym-
phoma.12–20 While radiation therapy alone is known
to be ineffective, it has frequently been adminis-
tered to responding patients; it is difficult to eval-
uate whether and how much this has improved the
eventual outcome. The excellent results obtained in
the GELA studies14 without radiation therapy have
questioned its necessity. In centers that have used
both first-generation chemotherapy regimens such
as CHOP, and the more aggressive third-generation
ones such as MACOP-B, the results have clearly
favored the latter. Todeschini et al.15 used CHOP
without achieving a single CR; in contrast, with
MACOP-B or F-MACHOP (5-fluorouracil, metho-
trexate, cytosine arabinoside, cyclophosphamide,
doxorubicin, vincristine, and prednisone)41 regimens,
87% of patients achieved a CR. Lazzarino et al.13
reported a CR rate after CHOP of 36%, while that
after MACOP-B or VACOP-B was 73%. In a multi-
center study of 106 patients, the 3 year-RFS was
38% with CHOP, while it was 58% with MACOP-B
or VACOP-B.18 In two previous studies25,26 we used
the MACOP-B regimen in 50 patients (a two-center
prospective trial) and in 89 patients (an Italian mul-
ticenter prospective trial) and obtained CR rates of
86% and 88%, respectively, while the 5-year RFS
rates were 93% and 91%, respectively.
In this retrospective multinational study compar-
ing first-generation, third-generation and high-dose
induction chemotherapy strategies, the more recent
strategies provided slightly better initial response
rates. In particular, the CR rates were 53% after HDS
or ABMT, 51% after MACOP-B or other third-gen-
eration protocols and 49% after CHOP or CHOP-like
regimens; overall response rates were 88%, 87%
and 81%, respectively. Among the patients who
achieved PR, 124 (84%) were submitted to radiation
therapy, and 100 (81%) of them obtained a CR sta-
tus. After this, the eventual CR rates became 75%
for the high-dose chemotherapy subgroup, 79% for
the third-generation one and only 61% for the first-
generation subgroup. After a median follow-up of
over 3 years, relapses have occurred in 23% of the
patients treated with first-generation regimens, as
against only 12% of those treated with the third-
generation ones and 0% among the high-dose
chemotherapy subgroup (p=0.004 among the 3 dif-
ferent chemotherapeutic subsets and p=0.02
between CHOP and MACOP-B). Survival analysis
clearly indicates the superiority of the third-gener-
ation approaches over the first-generation ones. In
particular, after median follow-ups of over 4 years,
the projected 10-year OS and PFS of the third-gen-
eration chemotherapy group are 71% and 67%,
respectively, as against only 44% and 35% in the
first-generation group (p=0.0001 and p=0.0003,
respectively). The survival data of the high-dose
chemotherapy subgroup also appear encouraging:
after median follow-ups of over 2.5 years, the pro-
jected 10-year OS and PFS are 77% and 78%,
respectively. At multivariate analysis five prognos-
tic factors for poor OS were identified: increasing
age, male sex, poor performance status, advanced
stage and the different chemotherapy induction.
To our knowledge, the present study describes the
largest series of patients with PMLBCL with sclero-
sis yet reported. The survival data, in particular,
strongly reinforce the concept that third-genera-
tion chemotherapy regimens (MACOP-B or MACOP-
B like) are better than first-generation (CHOP or
CHOP-like) ones in terms of both OS and PFS. Third-
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Table 5. Multivariate analysis of poor prognostic factors
that influence OS.
p-value Exp(B) 95% CI
Increasing age 0.0002 1.02 1.01-1.03
Male sex 0.02 1.49 1.05-2.12
Poor performance status 0.001 0.51 0.34-0.77
Advanced stage 0.004 0.57 0.39-0.83
Induction chemotherapy 0.0002 0.49 0.34-0.71
Figure 5. OS curves according to IPI score.
years
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generation regimens should now constitute the
induction strategy of choice in most cases. The
encouraging results of the high-dose chemothera-
py subgroup of patients are very interesting. How-
ever, in view of the low number of patients treated,
further studies are needed to assess the validity of
using HDS or ABMT in particularly high-risk sub-
sets. The present study also provides convincing evi-
dence that radiation therapy may be regarded as a
powerful tool for increasing the CR rate or rein-
forcing existing CRs after induction chemotherapy.
Concerning restaging, over 40% of patients have
residual radiographic abnormalities in the medi-
astinum even after CR, so chest radiographs and
computed tomography scans do not provide a valid
basis for therapeutic decision making. 67GaSPECT
and PET could be the best tools for selecting those
patients who really require the addition of radia-
tion therapy after chemotherapeutic induction.25,42,43
In conclusion, this retrospectve multinational
study on 426 patients with PMLBCL with sclerosis,
with a median follow-up of over 3 years, confirms
the superiority of the third-generation chemother-
apy strategies over first-generation ones in terms
of survival. While third-generation protocols should
now be the induction treatment of choice in the
majority of cases, high-dose approaches (including
ABMT) may be considered in particularly high-risk
patients. Prospective randomized studies are need-
ed to confirm the validity of this promising thera-
peutic option. Our study also highlights the role of
radiation therapy (preferably after 67GaSPECT and/or
PET restaging) for converting cases of PR to CR, and
probably also of reinforcing existing CRs. Our data
suggest that, with appropriate application of such
combined-modality therapy strategies, the long-
term OS of patients with PMLBCL with sclerosis may
be as high as 70-75%.
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What is already known on this topic
Primary mediastinal lymphoma is a recognized entity
among aggressive B-cell lymphomas. Whether or not
the treatment and the prognosis of this lymphoma sub-
type is different from other diffuse large B-cell lym-
phomas is a matter of debate.
What this study adds
This retrospective study constitutes the largest series of
mediastinal large cell lymphomas ever published and
indicates that about two-third of the patients are being
cured.
Potential implications for clinical practice
This retrospective analysis suggests that high-dose ther-
apy and radiotherapy may be of benefit for these
patients. These data should be interpreted keeping in
mind other randomized trials on these topics and the
therapeutic approaches should be tested in prospective
comparative studies.
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